Study of KK2223 for T-cell lymphoma after prior treatments
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a type of T-cell lymphoma called PTCL or CTCL.
- Your lymphoma must have come back or not responded to at least one prior treatment (for PTCL) or two prior treatments (for CTCL).
- You need to have a tumor sample from a past biopsy or surgery available for the study.
- You must have lymphoma that can be measured on scans or seen on your skin.
- You need to be in fairly good health overall, with normal blood counts, kidney function, and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
This is an early-stage study testing a new drug called KK2430 in people with blood cancers (like leukemia or lymphoma). The goal is to find the right dose and see if it helps shrink tumors.
This Phase 1 study tests whether TT-01488 is safe and tolerable in people with B-cell malignancies (blood cancers). It’s meant for patients whose disease has come back or did not respond after standard treatments.
This trial tests a new drug called TR115 against the standard treatment options for people with peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if TR115 can help shrink tumors and improve outcomes.
Hear when a new T-cell NHL (PTCL or CTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.